B.E., Beijing University of Chemical Technology, China (Biochemical Engineering)
PhD, Uppsala Biomedical Centre, Sweden (Molecular Biology)
Post-doctoral Fellow, Purdue University (Structural Biology)
Instructor, Howard Hughes Medical Institute, National Jewish Health (Immunology)
Affiliations
Member, Graduate Program in Immunology
Member, Graduate Program in Toxicology
Member, Graduate Program in Pharmaceutical Sciences
Member, Graduate Program in Structural Biology and Biochemistry
Member, Colorado Clinical and Translational Sciences Institute
Affiliate Member, University of Colorado Cancer Center
Faculty, Department of Immunology and Microbiology, School of Medicine
Faculty, Department of Biomedical Research, National Jewish Health
Research Interest
CAR T and engineered T cell therapies of autoimmune diseases
Mechanisms of T cell mediated metal hypersensitivities
Mechanisms of T cell recognition of autoantigens in Type 1 diabetes and RA
Redox signaling and drug design in the immune diseases and infectious diseases
Publications and Presentations
Salinas G, Gao W, Wang Y, Bonilla M, Yu L, Novikov A, Virginio VG, Ferreira HB, Vieites M, Gladyshev VN, Gambino D, Dai S. (2017) The Enzymatic and Structural Basis for Inhibition of Echinococcus granulosus Thioredoxin Glutathione Reductase by Gold(I). Antioxid Redox Signal. 27(18):1491-1504. (Cover Story)
Wang Y, Sosinowski T, Novikov A, Crawford F, Neau DB, Yang J, Kwok WW, Marrack P, Kappler JW, Dai S. (2018) C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A. 115(1):162-167.
Wang Y, Sosinowski T, Novikov A, Crawford F, White J, Jin N, Liu Z, Zou J, Neau DB, Davidson HW, Nakayama M, Kwok WW, Gapin L, Marrack P, Kappler JW, Dai S. (2019) How C-terminal additions to insulin B-chain fragments create super-agonists for T cells in mouse and human type-1 diabetes. Science Immunology, 2019 Apr 5;4(34). (Cover Story)
Skaggs School of Pharmacy and Pharmaceutical Sciences